Resource Library

Listen to our CEO & Founder, Derk Arts, as he reflects on lessons learned from the BIO panel discussion and what to expect at DIA.

As the adoption of real-world evidence (RWE) in healthcare continues to grow, and with the FDA embracing these trials more and more, researchers have come to appreciate the significance of establishing uniform approaches for evaluating and analyzing real-world data (RWD).

An avalanche of data from so many real-world sources is available today, with the promise of more data generated daily—so why not use it?

In this on-demand webinar we join forces with UBC & Datavant to dive deep into patient-centric technologies & tokenization in RWE studies.

As the adoption of real-world evidence (RWE) in healthcare continues to grow, and with the FDA embracing these trials more and more, researchers have come to appreciate the significance of establishing uniform approaches for evaluating and analyzing real-world data (RWD).

As the adoption of real-world evidence (RWE) in healthcare continues to grow, and with the FDA embracing these trials more and more, researchers have come to appreciate the significance of establishing uniform approaches for evaluating and analyzing real-world data (RWD).

As the adoption of real-world evidence (RWE) in healthcare continues to grow, and with the FDA embracing these trials more and more, researchers have come to appreciate the significance of establishing uniform approaches for evaluating and analyzing real-world data (RWD).

Castor announces the appointment of Brad Hightower, a leading clinical trials executive, to its advisory board.

As we kick-off 2023 with a refreshed mindset, we take inventory of what is important and focus on our goal to continuously make sure that we are maximizing the impact of data on the global disease burden with more inclusive, patient-friendly trials.